FDA Fast-Tracks Approval of Revolution Medicines' Pancreatic Cancer Pill, Rasonque
The U.S. Food and Drug Administration has approved daraxonrasib, a daily oral pill for metastatic pancreatic cancer, after an expedited review process. The drug, marketed as Rasonque, blocks the RAS protein that drives tumor growth and was shown to double median survival in clinical trials. It is now available in the U.S. at a price of $39,800 for a 30-day supply, with potential co-pay assistance for insured patients.
Key points
- The FDA granted expedited approval to daraxonrasib (brand name Rasonque) for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
- Clinical trials demonstrated that the drug doubled median overall survival, extending it from 6.7 months to 13.2 months compared to standard chemotherapy.
- The drug targets KRAS mutations, which are present in over 90% of pancreatic cancer cases, using a molecular glue mechanism to bind with multiple KRAS subtypes.
- The approval followed an expedited review process that took less than six months, significantly faster than the typical 10 to 12-month timeline.
- The drug is priced at $39,800 for a 30-day supply, with commercially insured patients potentially paying $0 through co-pay assistance programs.
Background
In August 2026, daraxonrasib was already being distributed to over 2,000 patients through the FDA's Expanded Access Program before formal approval. Earlier reports highlighted its potential to double survival in late-stage pancreatic cancer, with side effects including rash, diarrhea, and mouth sores. The drug's development involved significant research at the Dana-Farber Cancer Institute in Boston, where Dr. Brian Wolpin led key clinical trials.
How outlets are covering it
AP News and CNN both emphasize the drug's impact on survival rates and the expedited nature of the FDA approval. CNN highlights the financial implications, noting that Revolution Medicines' stock rose 166% this year and that analysts project $11.5 billion in annual sales. WCVB focuses on the local impact, highlighting the role of Dana-Farber Cancer Institute in the drug's development and featuring patient testimonials, such as Carla Walker, who reported a 40% shrinkage in her liver mass. All sources agree on the drug's potential to offer new hope to patients with a previously incurable form of cancer, but they differ in their emphasis on financial, clinical, and local aspects.
Why it matters
The approval of daraxonrasib represents a significant breakthrough in the treatment of pancreatic cancer, which has a five-year survival rate of only 13%. The drug's ability to double median survival and its rapid approval process could lead to improved outcomes for the approximately 67,000 patients diagnosed with pancreatic cancer in the U.S. this year. Additionally, the drug's success may pave the way for similar treatments in other cancers, such as lung cancer, and could influence future FDA approval processes for other life-threatening conditions.
What to watch
Revolution Medicines is expected to see significant revenue from Rasonque, with analysts projecting $28 million in Q3 and $148 million in Q4. The company is also studying the drug's technology for other forms of cancer, including lung cancer. Patients who were previously on the Expanded Access Program will now have broader access to the drug, and the FDA's expedited review process may be applied to other therapies addressing major health priorities.
- FDA approves landmark pancreatic cancer drug that’s shown to improve survival AP News
- F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer The New York Times
- Revolution Medicines gets FDA nod for targeted pancreatic cancer drug CNN
- FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease WSJ
- FDA approves first-of-a-kind pancreatic cancer drug trialed at Dana-Farber in Boston WCVB
Want the full story? Read the original reporting
Read on AP News